Abstract | BACKGROUND: METHODS: In the first part of the study, we asked physicians to answer a questionnaire presenting a hypothetical HF patient. In the second part, we reviewed hospital charts of patients with HF exacerbation. RESULTS: CONCLUSIONS: Despite good evidence, underutilization of aldosterone antagonists in patients matching the population of the RALES (Randomized Aldactone Evaluation Study) trial persists in both outpatient and inpatient settings. The difference between the usage of ACE inhibitors and spironolactone is significant in patients with systolic dysfunction equally qualifying for both medications.
|
Authors | Maya Guglin, Khaled Esmaeel Awad, Latha Polavaram, Hema Vankayala |
Journal | American journal of cardiovascular drugs : drugs, devices, and other interventions
(Am J Cardiovasc Drugs)
Vol. 7
Issue 1
Pg. 75-9
( 2007)
ISSN: 1175-3277 [Print] New Zealand |
PMID | 17355168
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Mineralocorticoid Receptor Antagonists
- Spironolactone
- Eplerenone
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Age Factors
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Drug Therapy, Combination
- Drug Utilization
(statistics & numerical data)
- Eplerenone
- Female
- Heart Failure
(drug therapy, physiopathology)
- Humans
- Inpatients
(statistics & numerical data)
- Male
- Middle Aged
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- Patient Discharge
(statistics & numerical data)
- Spironolactone
(analogs & derivatives, therapeutic use)
- Surveys and Questionnaires
|